3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
2
Renal Insufficiency
1
Interventions
Dexamethasone
374
Lenalidomide
206
Bortezomib
201
Cyclophosphamide
178
Melphalan
135
Calcium Dobesilate
120
daratumumab
107
pomalidomide
74
carfilzomib
74
fludarabine phosphate
71
Peripheral Blood Stem Cell Transplantation
66
Thalidomide
57
Filgrastim
57
Mycophenolic Acid
56
Busulfan
55
Tacrolimus
48
Granulocyte Colony-Stimulating Factor
47
ixazomib
45
fludarabine
45
Whole-Body Irradiation
44
dexamethasone acetate
36
Cyclosporine
35
isatuximab
34
Etoposide
34
Antilymphocyte Serum
32
dexamethasone 21-phosphate
30
elotuzumab
28
auricularum
27
Prednisone
27
plerixafor
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
melflufen
×
Plasma cell
×
Clear all
NCT03639610
2023-03-10
BRIDGE
Oncopeptides AB
Phase 2
Terminated
35 enrolled
33 charts
NCT02963493
2022-11-22
HORIZON
Oncopeptides AB
Phase 2
Completed
157 enrolled
26 charts
1 FDA